Replies to post #100178 on Biotech Values

[mcbio]

Re: ANDS - ANA598 SVR12 data

So, based on this PR, you don't believe that ANA598 has a chance to form the backbone of a monotherapy HCV treatment?

All kidding aside, the data isn't consequential to a large degree because it's SVR24, not SVR12, that is the key number, right? That longer timeframe is to account for the viral rebound that's not accounted for in just SVR12.